• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Epidemiol . Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS

tetano

Editor, Senior Moderator
Clin Epidemiol


. 2022 Mar 22;14:369-384.
doi: 10.2147/CLEP.S323292. eCollection 2022.
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS


Kristin Kostka[SUP] 1 2 [/SUP], Talita Duarte-Salles[SUP] 3 [/SUP], Albert Prats-Uribe[SUP] 4 [/SUP], Anthony G Sena[SUP] 5 6 [/SUP], Andrea Pistillo[SUP] 3 [/SUP], Sara Khalid[SUP] 4 [/SUP], Lana Y H Lai[SUP] 7 [/SUP], Asieh Golozar[SUP] 8 9 [/SUP], Thamir M Alshammari[SUP] 10 [/SUP], Dalia M Dawoud[SUP] 11 [/SUP], Fredrik Nyberg[SUP] 12 [/SUP], Adam B Wilcox[SUP] 13 14 [/SUP], Alan Andryc[SUP] 5 [/SUP], Andrew Williams[SUP] 15 [/SUP], Anna Ostropolets[SUP] 16 [/SUP], Carlos Areia[SUP] 17 [/SUP], Chi Young Jung[SUP] 18 [/SUP], Christopher A Harle[SUP] 19 [/SUP], Christian G Reich[SUP] 1 2 [/SUP], Clair Blacketer[SUP] 5 6 [/SUP], Daniel R Morales[SUP] 20 [/SUP], David A Dorr[SUP] 21 [/SUP], Edward Burn[SUP] 3 4 [/SUP], Elena Roel[SUP] 3 22 [/SUP], Eng Hooi Tan[SUP] 4 [/SUP], Evan Minty[SUP] 23 [/SUP], Frank DeFalco[SUP] 5 [/SUP], Gabriel de Maeztu[SUP] 24 [/SUP], Gigi Lipori[SUP] 19 [/SUP], Hiba Alghoul[SUP] 25 [/SUP], Hong Zhu[SUP] 26 [/SUP], Jason A Thomas[SUP] 13 [/SUP], Jiang Bian[SUP] 19 [/SUP], Jimyung Park[SUP] 27 [/SUP], Jordi Martínez Roldán[SUP] 28 [/SUP], Jose D Posada[SUP] 29 [/SUP], Juan M Banda[SUP] 30 [/SUP], Juan P Horcajada[SUP] 31 [/SUP], Julianna Kohler[SUP] 32 [/SUP], Karishma Shah[SUP] 33 [/SUP], Karthik Natarajan[SUP] 16 34 [/SUP], Kristine E Lynch[SUP] 35 36 [/SUP], Li Liu[SUP] 37 [/SUP], Lisa M Schilling[SUP] 38 [/SUP], Martina Recalde[SUP] 3 22 [/SUP], Matthew Spotnitz[SUP] 14 [/SUP], Mengchun Gong[SUP] 39 [/SUP], Michael E Matheny[SUP] 40 41 [/SUP], Neus Valveny[SUP] 42 [/SUP], Nicole G Weiskopf[SUP] 21 [/SUP], Nigam Shah[SUP] 29 [/SUP], Osaid Alser[SUP] 43 [/SUP], Paula Casajust[SUP] 42 [/SUP], Rae Woong Park[SUP] 27 44 [/SUP], Robert Schuff[SUP] 21 [/SUP], Sarah Seager[SUP] 1 [/SUP], Scott L DuVall[SUP] 35 36 [/SUP], Seng Chan You[SUP] 45 [/SUP], Seokyoung Song[SUP] 46 [/SUP], Sergio Fernández-Bertolín[SUP] 3 [/SUP], Stephen Fortin[SUP] 5 [/SUP], Tanja Magoc[SUP] 19 [/SUP], Thomas Falconer[SUP] 16 [/SUP], Vignesh Subbian[SUP] 47 [/SUP], Vojtech Huser[SUP] 48 [/SUP], Waheed-Ul-Rahman Ahmed[SUP] 33 49 [/SUP], William Carter[SUP] 38 [/SUP], Yin Guan[SUP] 50 [/SUP], Yankuic Galvan[SUP] 19 [/SUP], Xing He[SUP] 19 [/SUP], Peter R Rijnbeek[SUP] 6 [/SUP], George Hripcsak[SUP] 16 34 [/SUP], Patrick B Ryan[SUP] 5 16 [/SUP], Marc A Suchard[SUP] 51 [/SUP], Daniel Prieto-Alhambra[SUP] 4 [/SUP]



Affiliations

Abstract

Purpose: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) Characterizing Health Associated Risks and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD.
Patients and methods: We conducted a descriptive retrospective database study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11th June 2020 and are iteratively updated via GitHub. We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19, and 113,627 hospitalized with COVID-19 requiring intensive services.
Results: We aggregated over 22,000 unique characteristics describing patients with COVID-19. All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts and are readily available online. Globally, we observed similarities in the USA and Europe: more women diagnosed than men but more men hospitalized than women, most diagnosed cases between 25 and 60 years of age versus most hospitalized cases between 60 and 80 years of age. South Korea differed with more women than men hospitalized. Common comorbidities included type 2 diabetes, hypertension, chronic kidney disease and heart disease. Common presenting symptoms were dyspnea, cough and fever. Symptom data availability was more common in hospitalized cohorts than diagnosed.
Conclusion: We constructed a global, multi-centre view to describe trends in COVID-19 progression, management and evolution over time. By characterising baseline variability in patients and geography, our work provides critical context that may otherwise be misconstrued as data quality issues. This is important as we perform studies on adverse events of special interest in COVID-19 vaccine surveillance.

Keywords: OHDSI; OMOP CDM; descriptive epidemiology; open science; real world data; real world evidence.
 
Back
Top Bottom